The loss of Global Blood Therapeutics under GAAP for 9 months of 2020 was $185.747 million, an increase of 8.8% compared to $170.791 million in the previous year. Revenue amounted to $82.508 million. The Company did not receive any revenue in the same period last year.
The loss of Global Blood Therapeutics under GAAP for 9 months of 2020 was $185.747 million, an increase of 8.8% compared to $170.791 million in the previous year. Revenue amounted to $82.508 million. The Company did not receive any revenue in the same period last year. 
ir.gbt.com
English (US) 